Announcements Trials
Browse Landscape

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Observational 1

Sponsor

Cancer Type

Classical hematology 1

Conditions

Carcinoma, Non-Small-Cell Lung 501Neoplasms 304Breast Neoplasms 298Colorectal Neoplasms 230Neoplasm Metastasis 196Prostatic Neoplasms 175Ovarian Neoplasms 173Lung Neoplasms 160Multiple Myeloma 159Recurrence 134Melanoma 125Pancreatic Neoplasms 116Squamous Cell Carcinoma of Head and Neck 105Stomach Neoplasms 103Leukemia, Myeloid, Acute 102Endometrial Neoplasms 102Small Cell Lung Carcinoma 89Leukemia, Lymphocytic, Chronic, B-Cell 87Triple Negative Breast Neoplasms 85Lymphoma, Non-Hodgkin 85Carcinoma, Renal Cell 83Carcinoma, Hepatocellular 79Urinary Bladder Neoplasms 77Lymphoma, Large B-Cell, Diffuse 74Lymphoma, Follicular 68Advanced Solid Tumors 66Parkinson Disease 4, Autosomal Dominant Lewy Body 62Lymphoma 62Glioblastoma 59Head and Neck Neoplasms 57

Interventions

ravulizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Atypical Hemolytic Uremic Syndrome × 90 days × Clear all
NCT06312644 2026-04-16

Study of UltomirisĀ® (Ravulizumab) Safety in Pregnancy

Alexion Pharmaceuticals, Inc.

Recruiting
75 enrolled
Classical hematology

Hemoglobinuria, Paroxysmal, Myasthenia Gravis, Neuromyelitis Optica, Atypical Hemolytic Uremic Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon ⚔